Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability

ChemMedChem

Volumn 8, Issue 2, 2013, Pages 272-279

  Cho, Misun ^a   Choi, Eunhyun ^b   Yang, Jee Sun ^a   Lee, Chulho ^a   Seo, Jeong Jea ^a   Kim, Beom Seok ^a   Oh, Soo Jin ^c   Kim, Hwan Mook ^d   Lee, Kiho ^e   Park, Song Kyu ^e   Kwon, Ho Jeong ^a   Han, Gyoonhee ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Gachon University   (South Korea)

^e Korea University   (South Korea)

Author keywords

Conjugation; Drug design; Histone deacetylases; Inhibitors; Metabolism; Pyridones

Indexed keywords

3 (1 BENZYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL) N HYDROXYACRYLAMIDE; 3 [1 (3 (BIPHENYL 4 YL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]N HYDROXYACRYLAMIDE; 3 [1 (BIPHENYL 4 YLMETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL] N HYDROXYACRYLAMIDE; 3 [1 [2 (BIPHENYL 4 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL] N HYDROXYACRYLAMIDE; 3 [1 [3 (BIPHENYL 4 YL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL) N HYDROXYACRYLAMIDE; HISTONE DEACETYLASE INHIBITOR; METHYL 3 (1 BENZYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)ACRYLATE; METHYL 3 (2 OXO 1,2 DIHYDROPYRIDIN 3 YL)ACRYLATE; METHYL 3 [1 (4 METHYLBENZYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 (4 METHYLPHENETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3YL)ACRYLATE; METHYL 3 [1 (4 METHYLPHENETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3YL]ACRYLATE; METHYL 3 [1 (BIPHENYL 4 YLMETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 (NAPHTHALEN 1 YLMETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 [2 (BIPHENYL 4 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 [2 (NAPHTHALEN 1 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 [2 (NAPHTHALEN 2 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)ACRYLATE; METHYL 3 [1 [2 (NAPHTHALEN 2 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 [3 (BIPHENYL 4 YL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [1 [3 (NAPHTHALEN 2 YL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; METHYL 3 [2 OXO 1 (3 PHENYLPROPYL) 1,2 DIHYDROPYRIDIN 3 YL]ACRYLATE; N HYDROXY 3 (1 (NAPHTHALEN 1 YLMETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 (2 OXO 1 PHENETHYL 1,2 DIHYDROPYRIDIN 3 YL)ACRYLAMIDE; N HYDROXY 3 [1 (4 METHYLPHENETHYL) 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [1 (NAPHTHALEN 1 YLMETHYL)2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [1 [2 (NAPHTHALEN 1 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [1 [2 (NAPHTHALEN 2 YL)ETHYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [1 [3 (NAPHTHALEN 2 YL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [2 OXO 1 (3 PHENYLPROPYL) 1,2 DIHYDROPYRIDIN 3YL]ACRYLAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONJUGATION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; LIVER MICROSOME; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; NEOPLASMS; PYRIDONES;

EID: 84873805830     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200529     Document Type: Article

References (33)

1. P. A. Jones, S. B. Baylin, Cell 2007, 128, 683-692.
2. T. Kouzarides, Cell 2007, 128, 693-705;
3. R. W. Johnstone, Nat. Rev. Drug Discovery 2002, 1, 287-299.
4. B. Venugopal, T. R. Evans, Curr. Med. Chem. 2011, 18, 1658-1671;
5. M. A. Glozak, E. Seto, Oncogene 2007, 26, 5420-5432.
6. J. E. Bolden, M. J. Peart, R. W. Johnstone, Nat. Rev. Drug Discovery 2006, 5, 769-784.
7. W. S. Xu, R. B. Parmigiani, P. A. Marks, Oncogene 2007, 26, 5541-5552.
8. O. Witt, H. E. Deubzer, M. Lodrini, T. Milde, I. Oehme, Curr. Pharm. Des. 2009, 15, 436-447.
9. O. Witt, H. E. Deubzer, T. Milde, I. Oehme, Cancer Lett. 2009, 277, 8-21.
10. S. Minucci, P. G. Pelicci, Nat. Rev. Cancer 2006, 6, 38-51.
11. J. Luo, F. Su, D. Chen, A. Shiloh, W. Gu, Nature 2000, 408, 377-381;
12. A. Ito, Y. Kawaguchi, C. H. Lai, J. J. Kovacs, Y. Higashimoto, E. Appella, T. P. Yao, EMBO J. 2002, 21, 6236-6245.
13. C. Hubbert, A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang, T. P. Yao, Nature 2002, 417, 455-458.
14. M. W. Anders, W. Dekant, Adv. Pharmacol. 1994, 27, 431-448.
15. P. A. Marks, R. Breslow, Nat. Biotechnol. 2007, 25, 84-90.
16. T. Suzuki, A. Matsuura, A. Kouketsu, H. Nakagawa, N. Miyata, Bioorg. Med. Chem. Lett. 2005, 15, 331-335;
17. T. Suzuki, Y. Nagano, A. Matsuura, A. Kohara, S. Ninomiya, K. Kohda, N. Miyata, Bioorg. Med. Chem. Lett. 2003, 13, 4321-4326.
18. P. R. Venkatesh, E. Goh, P. Zeng, L. S. New, L. Xin, M. K. Pasha, K. Sangthongpitag, P. Yeo, E. Kantharaj, Biol. Pharm. Bull. 2007, 30, 1021-1024.
19. L. Du, D. G. Musson, A. Q. Wang, J. Pharm. Biomed. Anal. 2006, 42, 556-564.
20. E. Choi, C. Lee, J. E. Park, J. J. Seo, M. Cho, J. S. Kang, H. M. Kim, S. K. Park, K. Lee, G. Han, Bioorg. Med. Chem. Lett. 2011, 21, 1218-1221;
21. H. M. Kim, K. Lee, B. W. Park, D. K. Ryu, K. Kim, C. W. Lee, S. K. Park, J. W. Han, H. Y. Lee, H. Y. Lee, G. Han, Bioorg. Med. Chem. Lett. 2006, 16, 4068-4070;
22. H. M. Kim, S. H. Hong, M. S. Kim, C. W. Lee, J. S. Kang, K. Lee, S. K. Park, J. W. Han, H. Y. Lee, Y. Choi, H. J. Kwon, G. Han, Bioorg. Med. Chem. Lett. 2007, 17, 6234-6238;
23. C. Lee, E. Choi, M. Cho, B. Lee, S. J. Oh, S. K. Park, K. Lee, H. M. Kim, G. Han, Bioorg. Med. Chem. Lett. 2012, 22, 4189-4192;
24. H. C. Yoon, E. Choi, J. E. Park, M. Cho, J. J. Seo, S. J. Oh, J. S. Kang, H. M. Kim, S. K. Park, K. Lee, G. Han, Bioorg. Med. Chem. Lett. 2010, 20, 6808-6811.
25. J. S. Yang, T.-G. Chun, K.-Y. Nam, H. M. Kim, G. Han, Bull. Korean Chem. Soc. 2012, 33, 2063-2066.
26. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S. C. Berghs, N. Carey, P. W. Finn, L. S. Collins, A. Tumber, J. W. Ritchie, P. B. Jensen, H. S. Lichenstein, M. Sehested, Biochem. J. 2008, 409, 581-589.
27. H. M. Kim, S. J. Oh, S. K. Park, G. Han, K. Kim, K. S. Lee, J. S. Kang, M. Nam, K. Lee, Xenobiotica 2008, 38, 281-293.
28. D. M. Jerina, J. W. Daly, Science 1974, 185, 573-582.
29. R. B. Silverman, The Organic Chemistry of Drug Design and Drug Action, 2nded., Elsevier, Burlington, 2004, pp.418-427.
30. A. E. Nassar, A. M. Kamel, C. Clarimont, Drug Discovery Today 2004, 9, 1020-1028.
31. J. C. Bressi, A. J. Jennings, R. Skene, Y. Wu, R. Melkus, R. DeJong, S. O'Connell, C. E. Grimshaw, M. Navre, A. R. Gangloff, Bioorg. Med. Chem. Lett. 2010, 20, 3142-3145.
32. J. D. Dignam, R. M. Lebovitz, R. G. Roeder, Nucleic Acids Res. 1983, 11, 1475-1489.
33. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, M. R. Boyd, J. Natl. Cancer Inst. 1990, 82, 1107-1112.